From injection therapies to natalizumab: Views on the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 2, 2012, Pages 97-104

  Bomprezzi, Roberto ^a   Okuda, Darin T ^a   Alderazi, Yazan J ^a   Stave, Olaf ^a   Frohman, Elliot M ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

JC virus serology; multiple sclersis; natalizumab; progressive multifocal leukoencephalopathy

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; RITUXIMAB;

CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PEER REVIEW; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; REVIEW;

EID: 84858635267     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611431289     Document Type: Article

References (48)

1. Alderazi Y.J. Campagnolo D. Bomprezzi R. (2011) Extended interval dosing of natalizumab: a single center experience. Am Acad Neurol Abstract P07.200.
2. Bates D. (2011) Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short term trials. Neurology 76: S14–S25.
3. Berger J.R. (2011) Too much of a good thing? IRIS with natalizumab-associated PML. Neurology 77: 1033–1034.
4. Bielekova B. Becker B.L. (2010) Monoclonal antibodies in MS: mechanisms of action. Neurology 74(Suppl. 1): S31–S40.
5. Biogen Idec (2011) Medical information website, https://medinfo.biogenidec.com/
6. Birnbaum G. (2010) Current and future treatments for relapsing remitting multiple sclerosis. Curr Opin Drug Discov Devel 13: 214–225.
7. Castillo-Trivino T. Mowry E.M. Gajofatto A. Chabas D. Crabtree-Hartman E. Cree B.A. et al. (2011) Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PloS ONE 6: e16664.
8. Cohen J.A. Rovaris M. Goodman A.D. Ladkani D. Wynn D. Filippi M., for the 9006 Study Group (2007) Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology 68: 939–944.
9. Coyle P.K. (2008 a) Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 71: S3–S7.
10. Coyle P.K. (2008 b) Switching algorithms: from one immunomodulatory agent to another. J Neurol 255(Suppl. 1): 44–50.
11. Durelli L. Verdun E. Barbero P. Bergui M. Versino E. Ghezzi A. et al. for the Independent Comparison of Interferon (INCOMIN) Trial Study Group (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359: 1453–1460.
12. EU Clinical Trials Register (2011) A randomized, blinded, parallel-group, phase 2 study exploring the safety, tolerability and efficacy of multiple regimens of natalizumab in adult subjects with relapsing multiple sclerosis. EudraCT Number: 2010-024000-10; Sponsor Protocol number: 101MS206, https://www.clinicaltrialsregister.eu
13. Fisniku L.K. Brex P.A. Altmann D.R. Miszkiel K.A. Benton C.E. Lanyon R. et al. (2008) Disability and T 2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131: 808–817.
14. Foley J. (2011) Progressive escalation of natalizumab serum concentration as a potential kinetic marker for PML risk assessment. Oral communication. Am Acad Neurol Abstract S51.004.
15. Fox R.J. Kappos L. Cree B. Kaufman M. Jeffrey D. Weinstock-Guttman B. et al. (2011) Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study. In ECTRIMS, abstract 150.
16. Giovannoni G. (2011) Promising emerging therapies for multiple sclerosis. Neurol Clin 29: 435–448.
17. Goodin D.S. (2008) Disease-modifying therapy in multiple sclerosis. Neurology 71: S8–S13.
18. Gorelik L. Lerner M. Bixler S. Crossman M. Schlain B. Simon K. et al. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295–303.
19. Jacobs L.D. Beck R.W. Simon J.H. Kinkel R.P. Brownscheidle C.M. Murray T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898–904.
20. Kappos L. Bates D. Edan G. Eraksoy M. Garcia-Merino A. Grigoriadis N. et al. (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10: 745–758.
21. Kappos L. Freedman M.S. Polman C.H. Edan G. Hartung H.P. Miller D.H. et al. for the BENEFIT Study Group (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8: 987–997.
22. Khan O. (2009) What can be learned from open direct comparative trials in multiple sclerosis? J Neurol Sci 277(Suppl. 1): S25–S28.
23. Khatri B.O. Man S. Giovannoni G. Koo A.P. Lee J.C. Tucky B. et al. (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402–409.
24. Kinkel R.P. Kollman C. O'Connor P. Murray T.J. Simon J. Arnold D. et al. for the CHAMPIONS Study Group (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678–684.
25. Langer-Gould A. Atlas S.W. Green A.J. Bollen A.W. Pelletier D. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353: 375–381.
26. Mikol D.D. Barkhof F. Chang P. Coyle P.K. Jeffery D.R. Schwid S.R. et al. (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7: 903–914.
27. Miller D.H. Soon D. Fernando K.T. MacManus D.G. Barker G.J. Yousry T.A. et al. for the AFFIRM Investigators (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68: 1390–1401.
28. Montalban X. Tintoré M. Swanton J. Barkhof F. Fazekas F. Filippi M. et al. (2010) MRI criteria for MS in patients with clinically isolated syndromes. Neurology 74: 427-434.
29. O'Connor P. Filippi M. Arnason B. Comi G. Cook S. Goodin D. et al. for the BEYOND Study Group (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8: 889–897.
30. O'Connor P.W. Goodman A. Kappos L. Lublin F.D. Miller D.H. Polman C.H. et al. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76: 1858–1865.
31. Okuda D.T. Mowry E.M. Beheshtian A. Waubant E. Baranzini S.E. Goodin D.S. et al. (2009) Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 72: 800–805.
32. Okuda D.T. Mowry E.M. Cree B.A. Crabtree E.C. Goodin D.S. Waubant E. et al. (2011) Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 76: 686–692.
33. Panitch H. Goodin D.S. Francis G. Chang P. Coyle P.K. O'Connor P. et al. for the EVIDENCE (EVidence of Interferon Dose-response: European North American Compartative Efficacy) Study Group and University of British Columbia MS / MRI Research Group (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496–1506.
34. Pawate S. Sriram S. Brentwood H.M. (2011) Natalizumab in multiple sclerosis: a ‘drug holiday’ is less well tolerated than a regimen of every other month dosing. Am Acad Neurol Abstract P01.194.
35. Polman C.H. O'Connor P.W. Havrdova E.A. Havrdova E. Hutchinson M. Kappos L. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
36. Polman C.H. Reingold S.C. Edan G. Filippi M. Hartung H.P. Kappos L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58: 840–846.
37. Sandrock A. Hotermans C. Richman S. Natarajan A. Lee S. Plavina T. et al. (2011) Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Am Acad Neurol Abstract P03.248
38. Sangalli F. Moiola L. Bucello S. Annovazzi P. Rizzo A. Radaelli M. et al. (2011) Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 31(Suppl. 3): 299–302.
39. Stüve O. Bennett J.L. Hemmer B. Wiendl H. Racke M.K. Bar-Or A. et al. (2008) Pharmacological treatment of early multiple sclerosis. Drugs 68: 73–83.
40. Swanton J.K. Fernando K. Dalton C.M. Miszkiel K.A. Thompson A.J. Plant G.T. et al. (2006) Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psych 77: 830–833.
41. Swanton J.K. Rovira A. Tintore M. Altmann D.R. Barkhof F. Filippi M. et al. (2007) MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 6: 677–686.
42. Tan I.L. McArthur J.C. Clifford D.B. Major E.O. Nath A. (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77: 1061–1067.
43. Tintoré M. (2007) Early MS treatment. Intern MS J 14: 5–10.
44. US National Institute of Health (2011) Clinical trials website, http://clinicaltrials.gov/ct2/show/NCT01067521?term=GALA&rank=1
45. Vellinga M.M. Castelijns J.A. Barkhof F. Uitdehaag B.M. Polman C.H. (2008) Postwithdrawal rebound increase in T 2 lesional activity in natalizumab-treated MS patients. Neurology 70: 1150–1151.
46. Vollmer T.L. Panitch H. Bar-Or A. Dunn J. Freedman M.S. Gazda S.K. et al. (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 14: 663–670.
47. Warnke C. Menge T. Hartung H.P. Racke M.K. Cravens P.D. Bennett J.L. et al. (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67: 923–930.
48. West T. Cree B.A. (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68: 395–399.